How effective is Fenelidone (Keshenda) in lowering urinary protein and its clinical efficacy evaluation

Finerenone (Finerenone) is a new type of non-steroidal selective mineral corticoid receptor antagonist (MRA), mainly used for the treatment of patients with chronic kidney disease (CKD) accompanied by 2 type diabetes. In clinical studies, Finerenone has been shown to have a significant inhibitory effect on proteinuria. Proteinuria is an important sign of the progression of chronic kidney disease. By reducing urinary protein excretion, it can delay the decline of renal function and reduce the risk of end-stage kidney disease (ESKD). Multiple randomized controlled trials have shown that Finerenone can significantly reduce urinary protein levels when compared with placebo, and shows a stable protein-lowering effect under different basic treatment backgrounds.

In large clinical trialsFIDELIO-DKD, Finerenone reduced urinary albumin/creatinine ratio (UACR) decreased on average by about 30%, showing a strong anti-proteinuric effect. This effect is not only reflected in the short-term reduction of urinary protein, but can also be maintained during long-term follow-up, helping to slow down the decline of renal function. At the same time, Finerenone also has a protective effect on the cardiovascular system, reducing the incidence of heart failure, myocardial infarction and other events, providing additional benefits to high-risk CKD patients.

From the perspective of efficacy evaluation, Finerenone not only reduces urinary protein, but also significantly delays the decline of renal function. Study data show that compared with the placebo group, the risk of the renal composite endpoint (including an increase in serum creatinine ≥ 40%, the need for renal replacement therapy, and renal death) in the Finerenone treatment group was reduced by approximately 18%. In addition, the drug has a good safety profile, can effectively reduce the risk of hyperkalemia when used at low doses, and is more tolerable and controllable than traditional steroid MRAs.

In summary, Finerenone shows good urinary protein-lowering effect and renal protection in patients with chronic kidney disease and proteinuria. Its significant proteinuria improvement and cardiorenal comprehensive benefits make it a current treatment for CKDAn important treatment option for patients, especially those with diabetes. With the accumulation of more long-term follow-up data in the future, the application prospects of Finerenone in clinical practice will be further clarified, providing a more accurate and safe solution for kidney disease management.

Reference link:https://www.drugs.com